Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma

Table 2 Treatment outcome in patients receiving regular or split-dose FMP therapy

		Patients achieving disease control
		Responders				Patients with progressive disease
Group	Total	CR	PR	MR	SD
Regular	27	2	4	3	5	13 (48.1%)
Split-dose	38	0	4	5	3	26 (68.4%)

Regular vs. split-dose protocol: disease control rate, P = 0.127; response rate, P = 0.414.

ISSN: 1471-2407